|
| LETTER TO EDITOR |
|
|
|
| Year : 2005 | Volume
: 71
| Issue : 1 | Page : 45-46 |
Generalized hypopigmentation due to imatinib: A fairness boon?
Atul Sharma, Amish Vora, Manisha Bhutani
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical sciences, New Delhi, India
Correspondence Address:
Atul Sharma
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi - 110 029
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0378-6323.13788
How to cite this article:
Sharma A, Vora A, Bhutani M. Generalized hypopigmentation due to imatinib: A fairness boon?. Indian J Dermatol Venereol Leprol 2005;71:45-6 |
How to cite this URL:
Sharma A, Vora A, Bhutani M. Generalized hypopigmentation due to imatinib: A fairness boon?. Indian J Dermatol Venereol Leprol [serial online] 2005 [cited 2021 Jan 24];71:45-6. Available from: https://www.ijdvl.com/text.asp?2005/71/1/45/13788 |
Sir,
Imatinib (STI571, Glivec©) is a new selective tyrosine kinase inhibitor that is very useful in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). More side effects are being reported with its increasing use. We report generalized hypopigmentation with the use of this drug.
The majority of CML and GIST patients on imatinib mesylate experience some undesirable side effects that involve many organ systems in the body, including the skin. The most common dermatological side effects are periorbital edema and dermatitis. Facial edema, pruritus, erythema, dry skin, alopecia, night sweats and photosensitivity reaction are infrequently reported.[1]
Over 120 patients of CML or GIST are being treated with imatinib at our institute since 2001. For the last one year, during routine outdoor visits, many patients have been reporting that their skin was becoming fairer while on imatinib. We interviewed 26 patients regarding this side effect; 22 of the patients and their relatives confirmed this experience at varying durations of treatment (median 2 months; range 2 to 8 months). Three patients in whom the drug had to be discontinued because of different reasons reported that their skin complexion had reverted to the original one.
Skin biopsies were performed on seven of these ′fair′ patients. On H and E staining, even though melanin pigment was seen in all of these biopsy specimens, low melanin content was observed in two of them. In the absence of a pretreatment biopsy, quantification of the melanin pigmentation was not possible. Currently, we are doing electron microscopy and tyramine based tyrosinase assay on the skin biopsies performed pre- and post-imatinib treatment for quantification of the melanin deposition in melanosomes.
The exact mechanism for this generalized hypopigmentation with imatinib is not known. Apart from inhibiting a tyrosine kinase, the BCR-ABL oncoprotein, imatinib also inhibits platelet-derived growth factor receptors (PDGFRs) and c-KIT receptor tyrosine kinases.[2] The latter two kinases have important roles in normal pigmentation.[3] Certain hypopigmentary disorders like piebaldism and vitiligo are associated with mutations in the c-KIT gene causing alteration in the respective tyrosine kinases.[4] Tsao et al recently reported a similar finding.[5] However, we found hypopigmentation to be much more common than they did, possibly because it is more apparent in Blacks or Indians because of their otherwise dark skin complexion. Based on our observation, we hypothesize that inhibition of melanocyte c-KIT receptor tyrosine kinase by imatinib leads to generalized hypopigmentation. The long-term implications of this observation need to be studied. Meanwhile, it will be interesting to see whether topical use of imatinib is possible in the future.
| References | |  |
| 1. | Glivec* (imatinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; 2001.  |
| 2. | Buchdunger E, Cioffi CL, Law N, Stover D, Ohno Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI 571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45. |
| 3. | Luo D, Chen H, Searles G, Jimbow K. Coordinated mRNA expression of c-Kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit/ SCF-R. Melanoma Res 1995;5:303-9. [PUBMED] |
| 4. | Dippel E, Haas N, Grabbe J, Schadendorf D, Hamann K, Czarnetzki BM. Expression of the c-Kit receptor in hypomelanosis: A comparative study between piebaldism, nevus depigmentosus and vitiligo. Br J Dermatol 1995;132:182-9. [PUBMED] |
| 5. | Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483-7. |
| This article has been cited by | | 1 |
Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study |
|
| Mar Llamas-Velasco,Javier Fraga,Heinz Kutzner,Juan Luis Steegmann,Amaro García-Diez,Luis Requena | | Journal of Cutaneous Pathology. 2014; : n/a | | [Pubmed] | [DOI] | | | 2 |
Inhibitory effects of imatinib mesylate on human epidermal melanocytes |
|
| Y. Wang,Y. Zhao,L. Liu,L. Zhang,H. Xiao,K. Wu,Y. Xu,Y. Hu,H. Fu,W. Cao,Y. Luo,H. Huang | | Clinical and Experimental Dermatology. 2014; : n/a | | [Pubmed] | [DOI] | | | 3 |
Vitiligo-like lesions in an adult patient treated with Imatinib mesylate |
|
| C. Cerchione,R. Fabbricini,F. Pane,L. Luciano | | Leukemia Research. 2009; 33(8): e104 | | [Pubmed] | [DOI] | | | 4 |
Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome |
|
| Campbell, T., Felsten, L., Moore, J. | | Archives of Dermatology. 2009; 145(11): 1313-1316 | | [Pubmed] | | | 5 |
Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia |
|
| Aamer Aleem | | Hematology/Oncology and Stem Cell Therapy. 2009; 2(2): 358 | | [Pubmed] | [DOI] | | | 6 |
Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia |
|
| Aleem, A. | | Hematology/ Oncology and Stem Cell Therapy. 2009; 2(2): 358-361 | | [Pubmed] | | | 7 |
Vitiligo-like lesions in an adult patient treated with Imatinib mesylate |
|
| Cerchione, C., Fabbricini, R., Pane, F., Luciano, L. | | Leukemia Research. 2009; 33(8): e104-e105 | | [Pubmed] | | | 8 |
Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors |
|
| Han, H., Yu, Y.-y., Wang, Y.-h. | | Journal of the American Academy of Dermatology. 2008; 59(5 Suppl): S80-S83 | | [Pubmed] | | | 9 |
Imatinib mesylate–induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors |
|
| Yang-yang Yu, Yu-hong Wang, Hui Han | | Journal of the American Academy of Dermatology. 2008; 59(5): S80 | | [VIEW] | [DOI] | | | 10 |
Hypopigmenting agents: An updated review on biological, chemical and clinical aspects |
|
| Solano F, Briganti S, Picardo M, Ghanem G | | Pigment Cell Research. 2006; 19(6): 550-571 | | [Pubmed] | | | 11 |
Hypopigmenting agents: an updated review on biological, chemical and clinical aspects |
|
| Francisco Solano,Stefania Briganti,Mauro Picardo,Ghanem Ghanem | | Pigment Cell Research. 2006; 19(6): 550 | | [Pubmed] | [DOI] | | | 12 |
Imatinib mesylate-induced generalized hypopigmentation in patients with chronic myeloid leukemia |
|
| Sunita, Gupta DK, Saluja S, Bhasin S, Sharma M | | Indian J Pharmacol. 2006; 38(1): 66-67 | | [Pubmed] | | | 13 |
Reporting of drug eruptions: The National Pharmacovigilance Program |
|
| Khopkar U | | Indian J Dermatol Venereol Leprol. 2005; 71(1): 1-2 | | [Pubmed] | |
|
|
|
|
|
|
|
|
